A Cross-Sectional Study of Patient Characteristics and Survival in Patients With Resectable Gallbladder Carcinoma

Document Type

Conference Proceeding

Publication Date

10-2024

Publication Title

American Journal of Gastroenterology

Abstract

Introduction: Gallbladder cancer (GBC) is a rare hepatobiliary malignancy. As GBC if often detected at advanced stages, the median survival is typically less than 1 year. Given its rarity, studies utilizing real-world patient data remains crucial. In this study, we aimed to identify patient characteristics and outcomes in patients with GBC who underwent curative surgery. Methods: All adult patients with GBC who had curative resection between years 2013-2023 at our institution were included. Demographic, clinical, treatment, and survival data were collected. Continuous variables are reported as median (interquartile range), and categorical variables reported as counts (%). Kaplan-Meier curves were used for survival analysis. P, 0.05 was considered as significant. Results: A total of 94 patients were included in the study. Median age was 71 (61.8-77.0) years, and 58 (61.7%) patients were female. Median tumor size was 3.3 (1.9-5.0) cm. Incidental GBC (IGBC) was seen in 46 (48.9%) patients and non-incidental GBC (NIGBC) in 48 (51.1%) patients. Of all patients, 12.8% had concomitant liver disease, and the age at diagnosis was significantly lower in patients with liver disease compared to without [61 (56-69) vs 72 (64-79), P50.003], respectively. Perineural invasion was seen in 48.9%, vascular invasion in 38.3%, and lymph node invasion in 37.2% of the patients. Positive surgical margin was present in 50% of the patients. A total of 60.6% of patients had adjuvant chemotherapy and 17% had radiotherapy. During the study period, 62 (66.0%) patients died, with a median survival of 1.9 years. Overall, 1-year survival was 68.7%, 3-year survival was 37.4%, and 5-year survival was 32.2%. Cholelithiasis was significantly more common in patients with IGBC (91.3%) compared to NIGBC (66.7%), P50.002, and the lymph node invasion was significantly more common in patients with IGBC (50%) compared to NIGBC (25%), P50.02. The median survival was 2.3 years in IGBC, compared to 1.6 years in NIGBC (P50.63). The 1-year survival rate was 68.9% in IGBC compared to 68.5% in NIGBC, 3-year survival was 39.1% in IGBC compared to 36.0% in NIGBC, and 5-year survival was 35.5% in IGBC compared to 28.8% in NIGBC. Conclusion: GBC is aggressive, and consistent with the prior reports, our study confirms the high rates of local and systemic involvement and high mortality. IGBC and NIGBC did not have significantly different survival difference. Real-world patient data remains important to identify patients at risk for worse outcomes (see Figure 1).

Volume

119

Issue

10S

First Page

S13

Comments

American College of Gastroenterology Annual Scientific Meeting, October 25-30, 2024, Philadelphia, PA

DOI

10.14309/01.ajg.0001028432.42261.99

Link to Full Text

Share

COinS